MLKL and Parkinson disease: The increased levels of RIPK1, RIPK3, and MLKL were also observed in the PD model (81); furthermore, the necrostatin-1, an inhibitor of necroptosis, improves the survival of optic atrophy type 1 mutant human iPSC–derived neurons in vitro and attenuate MPTP-induced dopaminergic neuron loss (9).